{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:36:12Z","timestamp":1794072972862,"version":"4.8.0"},"reference-count":166,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The development of coagulation factor VIII (FVIII) inhibitory antibodies is a serious complication in hemophilia A (HA) patients after FVIII replacement therapy. Inhibitors render regular prophylaxis ineffective and increase the risk of morbidity and mortality. Immune tolerance induction (ITI) regimens have become the only clinically proven therapy for eradicating these inhibitors. However, this is a lengthy and costly strategy. For HA patients with high titer inhibitors, bypassing or new hemostatic agents must be used in clinical prophylaxis due to the ineffective ITI regimens. Since multiple genetic and environmental factors are involved in the pathogenesis of inhibitor generation, understanding the mechanisms by which inhibitors develop could help identify critical targets that can be exploited to prevent or eradicate inhibitors. In this review, we provide a comprehensive overview of the recent advances related to mechanistic insights into anti-FVIII antibody development and discuss novel therapeutic approaches for HA patients with inhibitors.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1019275","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T15:18:25Z","timestamp":1670512705000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications"],"prefix":"10.3389","volume":"13","author":[{"given":"Liping","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: A meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/00024382-200115030-00013","article-title":"Definitions in hemophilia. recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the international society on thrombosis and haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-535328","article-title":"FVIII inhibitors: Pathogenesis and avoidance","volume":"125","author":"Astermark","year":"2015","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02266.x","article-title":"Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. 1977","volume":"16","author":"Brackmann","year":"2010","journal-title":"Haemophilia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14381","article-title":"Immune tolerance induction in severe haemophilia a: A UKHCDO inhibitor and paediatric working party consensus update","volume":"27","author":"Hart","year":"2021","journal-title":"Haemophilia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12730","article-title":"US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors","volume":"21","author":"Valentino","year":"2015","journal-title":"Haemophilia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13023-018-0800-z","article-title":"European Principles of inhibitor management in patients with haemophilia","volume":"13","author":"Giangrande","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3324\/haematolo.2004.%25x","article-title":"Use of implantable venous access devices in children with severe hemophilia: Benefits and burden","volume":"89","author":"Van Dijk","year":"2004","journal-title":"Haematologica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17677","article-title":"Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and real-world clinical practices","volume":"194","author":"Liu","year":"2021","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13143","article-title":"Inhibitor recurrence after immune tolerance induction: A multicenter retrospective cohort study","volume":"13","author":"Antun","year":"2015","journal-title":"J Thromb Haemost"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia a patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2141.2006.06359.x","article-title":"Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia a and factor VIII inhibitors","volume":"136","author":"Reipert","year":"2007","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/12483","article-title":"Catalytic activity of antibodies against factor VIII in patients with hemophilia a","volume":"5","author":"Lacroix-Desmazes","year":"1999","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-160432","article-title":"How we treat a hemophilia a patient with a factor VIII inhibitor","volume":"113","author":"Kempton","year":"2009","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12016-009-8119-0","article-title":"Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies","volume":"37","author":"Lavigne-Lissalde","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00674.x","article-title":"Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia a","volume":"8","author":"Lindgren","year":"2002","journal-title":"Haemophilia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-720086","article-title":"Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia a","volume":"129","author":"Cannavo","year":"2017","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002731","article-title":"The prospective hemophilia inhibitor PUP study reveals distinct antibody signatures prior to FVIII inhibitor development","volume":"4","author":"Reipert","year":"2020","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)01123-x","article-title":"The past and future of haemophilia: Diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.05.027","article-title":"Risk factors for inhibitor development in severe hemophilia a","volume":"168","author":"Garagiola","year":"2018","journal-title":"Thromb Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02420.x","article-title":"Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia a patients","volume":"17","author":"Gouw","year":"2011","journal-title":"Haemophilia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12723","article-title":"F8 gene mutation spectrum in severe hemophilia a with inhibitors: A large cohort data analysis from a single center in China","volume":"6","author":"Sun","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.903838","article-title":"Genome-wide association study and gene-based analysis of participants with hemophilia a and inhibitors in the my life, our future research repository","volume":"9","author":"Lessard","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03636.x","article-title":"Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia a","volume":"7","author":"Pavlova","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01219","article-title":"Hemophilia a inhibitor subjects show unique PBMC gene expression profiles that include up-regulated innate immune modulators","volume":"11","author":"Karim","year":"2020","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02828.x","article-title":"Incidence of factor VIII inhibitors in severe haemophilia: The importance of patient age","volume":"113","author":"Lorenzo","year":"2001","journal-title":"Br J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02464.x","article-title":"Recombinant factor concentrates may increase inhibitor development: A single centre cohort study","volume":"17","author":"Strauss","year":"2011","journal-title":"Haemophilia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009209","article-title":"The impact of von willebrand factor on factor VIII memory immune responses","volume":"1","author":"Chen","year":"2017","journal-title":"Blood Adv"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02679.x","article-title":"Immunoprotective effect of von willebrand factor towards therapeutic factor VIII in experimental haemophilia a","volume":"18","author":"Delignat","year":"2012","journal-title":"Haemophilia"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia a","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13203","article-title":"SIPPET: methodology, analysis and generalizability","volume":"23","author":"Peyvandi","year":"2017","journal-title":"Haemophilia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia a: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia a: The RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia a: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002626","article-title":"Inhibitors and mortality in persons with nonsevere hemophilia a in the united states","volume":"4","author":"Lim","year":"2020","journal-title":"Blood Adv"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13711","article-title":"Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia a patients: Results of the INSIGHT case-control study","volume":"15","author":"van Velzen","year":"2017","journal-title":"J Thromb Haemost"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1621717","article-title":"Inhibitors in nonsevere hemophilia a: What is known and searching for the unknown","volume":"44","author":"Abdi","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483263","article-title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia a","volume":"122","author":"Eckhardt","year":"2013","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02595.x","article-title":"Treatment characteristics and the risk of inhibitor development: A multicenter cohort study among previously untreated patients with severe hemophilia a","volume":"5","author":"Gouw","year":"2007","journal-title":"J Thromb Haemost"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia a","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02629.x","article-title":"Risk of inhibitor development in mild haemophilia a increases with age","volume":"18","author":"Mauser-Bunschoten","year":"2012","journal-title":"Haemophilia"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15419","article-title":"Treatment-related risk factors for inhibitor development in non-severe hemophilia a after 50 cumulative exposure days: A case-control study","volume":"19","author":"Abdi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12990","article-title":"Inhibitor development and mortality in non-severe hemophilia a","volume":"13","author":"Eckhardt","year":"2015","journal-title":"J Thromb Haemost"},{"key":"B47","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00287","article-title":"The danger theory: 20 years later","volume":"3","author":"Pradeu","year":"2012","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1604213","article-title":"An update on the 'danger theory' in inhibitor development in hemophilia a","volume":"12","author":"Schep","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1189\/jlb.0306164","article-title":"DAMPs, PAMPs and alarmins: all we need to know about danger","volume":"81","author":"Bianchi","year":"2007","journal-title":"J Leukoc Biol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0607374","article-title":"Early events in the recognition of danger signals after tissue injury","volume":"83","author":"Kaczorowski","year":"2008","journal-title":"J Leukoc Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2003.12.020","article-title":"Immune activation: death, danger and dendritic cells","volume":"14","author":"Pulendran","year":"2004","journal-title":"Curr Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1160\/th17-03-0149","article-title":"Acute haemarthrosis in the haemophilia a rat generates a local and systemic proinflammatory response","volume":"117","author":"L\u00f6vgren","year":"2017","journal-title":"Thromb Haemost"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348458","article-title":"CD4, and liaisons dangereuses","volume":"117","author":"Ragni","year":"2011","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02122.x","article-title":"New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development","volume":"16","author":"Kurnik","year":"2010","journal-title":"Haemophilia"},{"key":"B56","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1182\/blood-2008-04-151597","article-title":"Anti-CD3 prevents factor VIII inhibitor development in hemophilia a mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response","volume":"113","author":"Waters","year":"2009","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1111\/jth.13800","article-title":"Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia a mice is CD4 T cell mediated","volume":"15","author":"Chen","year":"2017","journal-title":"J Thromb Haemost"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000650","article-title":"Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia a mice","volume":"3","author":"Jing","year":"2019","journal-title":"Blood Adv"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2020.001","article-title":"Molecular mechanisms of inhibitor development in hemophilia","volume":"12","author":"Tieu","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1989.29589284147.x","article-title":"Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC","volume":"29","author":"Ragni","year":"1989","journal-title":"Transfusion"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830420408","article-title":"Loss of high-responder inhibitors in patients with severe hemophilia a and human immunodeficiency virus type 1 infection: A report from the multi-center hemophilia cohort study","volume":"42","author":"Bray","year":"1993","journal-title":"Am J Hematol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001468","article-title":"Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice","volume":"4","author":"Shi","year":"2020","journal-title":"Blood Adv"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4230","article-title":"LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII","volume":"106","author":"Bovenschen","year":"2005","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008046200","article-title":"Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein","volume":"276","author":"Sarafanov","year":"2001","journal-title":"J Biol Chem"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2011.10.001","article-title":"Requirements for immune recognition and processing of factor VIII by antigen-presenting cells","volume":"26","author":"van Haren","year":"2012","journal-title":"Blood Rev"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.08.029","article-title":"Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain","volume":"129","author":"Herczenik","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022756","article-title":"VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors","volume":"109","author":"Dasgupta","year":"2007","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24513","article-title":"Exposure of FVIII in the presence of phosphatidyl serine reduces generation of memory b-cells and induces regulatory T-Cell-Mediated hyporesponsiveness in hemophilia a mice","volume":"104","author":"Ramakrishnan","year":"2015","journal-title":"J Pharm Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2010.10.006","article-title":"Phosphatidylserine reduces immune response against human recombinant factor VIII in hemophilia a mice by regulation of dendritic cell function","volume":"138","author":"Gaitonde","year":"2011","journal-title":"Clin Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C112.396325","article-title":"Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia a mice","volume":"288","author":"Gaitonde","year":"2013","journal-title":"J Biol Chem"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15497","article-title":"Tolerogenic form of factor VIII to prevent inhibitor development in the treatment of hemophilia a","volume":"19","author":"Nguyen","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.07.018","article-title":"Subcutaneous administration of lyso-phosphatidylserine nanoparticles induces immunological tolerance towards factor VIII in a hemophilia a mouse model","volume":"548","author":"Glassman","year":"2018","journal-title":"Int J Pharm"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005758","article-title":"Influence of n-glycosylation in the a and c domains on the immunogenicity of factor VIII","volume":"6","author":"Vander Kooi","year":"2022","journal-title":"Blood Adv"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03571.x","article-title":"Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia a","volume":"7","author":"Navarrete","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782912","article-title":"Marginal zone b cells are critical to factor VIII inhibitor formation in mice with hemophilia a","volume":"130","author":"Zerra","year":"2017","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.9.2750","article-title":"Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia a","volume":"97","author":"Rossi","year":"2001","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cellimm.2015.10.001","article-title":"In vivo induction of regulatory T cells for immune tolerance in hemophilia","volume":"301","author":"Wang","year":"2016","journal-title":"Cell Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: Immunosuppression of FVIII-specific T- and b-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.10.33","article-title":"Immunomodulation for inhibitors in hemophilia a: the important role of treg cells","volume":"3","author":"Miao","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1538-7836.2009.03417.x","article-title":"Role of regulatory T cells in tolerance to coagulation factors","author":"Cao","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159925","article-title":"Immune tolerance against infused FVIII in hemophilia a is mediated by PD-L1 + regulatory T cells","volume":"132","author":"Becker-Gotot","year":"2022","journal-title":"J Clin Invest"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142906","article-title":"B cell-activating factor modulates the factor VIII immune response in hemophilia a","volume":"131","author":"Doshi","year":"2021","journal-title":"J Clin Invest"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02736.x","article-title":"Factor VIII-specific memory b cells in patients with hemophilia a","volume":"5","author":"van Helden","year":"2007","journal-title":"J Thromb Haemost"},{"key":"B84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1365-2516.2010.02215.x","article-title":"Factor VIII-specific b cell responses in haemophilia a patients with inhibitors","volume":"16","author":"van Helden","year":"2010","journal-title":"Haemophilia"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1126\/science.1076071","article-title":"Maintenance of serological memory by polyclonal activation of human memory b cells","volume":"298","author":"Bernasconi","year":"2002","journal-title":"Science"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.03.016","article-title":"Plasma cell differentiation and survival","volume":"20","author":"Tarlinton","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/hae.13445","article-title":"Immune tolerance induction: What have we learned over time","volume":"24","author":"Brackmann","year":"2018","journal-title":"Haemophilia"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03078","article-title":"Factor VIII: Perspectives on immunogenicity and tolerogenic strategies","volume":"10","author":"Scott","year":"2019","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-369132","article-title":"International immune tolerance s. the principal results of the international immune tolerance study: A randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00476","article-title":"Escape or fight: Inhibitors in hemophilia a","volume":"11","author":"Merlin","year":"2020","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001832","article-title":"Maternal microchimerism protects hemophilia a patients from inhibitor development","volume":"4","author":"Lu","year":"2020","journal-title":"Blood Adv"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-662916","article-title":"The immunogenicity of platelet-derived FVIII in hemophilia a mice with or without preexisting anti-FVIII immunity","volume":"127","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1055\/a-1727-1384","article-title":"Emicizumab for all pediatric patients with severe hemophilia a","volume":"42","author":"Wieland","year":"2022","journal-title":"Hamostaseologie"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211032452","article-title":"Design of an international investigator-initiated study on MOdern treatment of inhibitor-positiVe pATiEnts with haemophilia a (MOTIVATE)","volume":"12","author":"Escuriola Ettingshausen","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia a with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII\u2013mimetic function of humanized bispecific antibody in hemophilia a","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia a with inhibitors: HAVEN 1 study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemophilia"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia a with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia a without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia a (HAVEN 4): A multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12670","article-title":"Prophylactic emicizumab for hemophilia a in the Asia-pacific region: A randomized study (HAVEN 5)","volume":"6","author":"Yang","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14205","article-title":"Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1\/2 study in patients with severe haemophilia a","volume":"27","author":"Shima","year":"2021","journal-title":"Haemophilia"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01200-2","article-title":"Emicizumab: A review in haemophilia a","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15226","article-title":"Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia a and inhibitor","volume":"19","author":"Valsecchi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12589","article-title":"Final analysis of the STASEY trial: A single-arm, multicenter, open-label, phase III clinical trial evaluating the safety and tolerability of emicizumab prophylaxis in persons with hemophilia a (PwHA) with factor (F)VIII inhibitors [abstract]","volume":"5","author":"Jim\u00e9nez-Yuste V","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14957","article-title":"Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia a with inhibitors: New case with detailed laboratory evaluation","volume":"18","author":"Harkins Druzgal","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14432","article-title":"Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia a with and without FVIII inhibitors","volume":"27","author":"Hassan","year":"2021","journal-title":"Haemophilia"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia a with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010331","article-title":"A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia a mice","volume":"138","author":"Ostergaard","year":"2021","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15682","article-title":"A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys","volume":"20","author":"Lauritzen","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-3848(16)30359-0","article-title":"Targeting TFPI for hemophilia treatment","author":"Peterson","year":"2016","journal-title":"Thromb Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.670526","article-title":"Progress in the development of anti-tissue factor pathway inhibitors for haemophilia management","volume":"8","author":"Mahlangu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14595","article-title":"Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating phase 2 study due to thrombosis","volume":"28","author":"Mancuso","year":"2022","journal-title":"Haemophilia"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia a and hemophilia A\/B with inhibitors: Phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/bloodadvances.2019001140","article-title":"Concizumab: a novel anti-TFPI therapeutic for hemophilia","volume":"5","author":"Shapiro","year":"2021","journal-title":"Blood Adv"},{"key":"B118","unstructured":"Novo Nordisk resumes phase 3 trials of concizumab in hemophilia a and b\n            ForestR\n          Hemophilia News Today2021"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006403","article-title":"Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia a and hemophilia A\/B with inhibitors","volume":"6","author":"Shapiro","year":"2022","journal-title":"Blood Adv"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18420","article-title":"A phase 1b\/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia","author":"Mahlangu","year":"2022","journal-title":"Br J Haematol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia a or b with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.442","article-title":"Non-factor therapies for bleeding disorders: A primer for the general haematologist","volume":"3","author":"Swan","year":"2022","journal-title":"EJHaem"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2572.2572","article-title":"Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: Updated results from a phase 1 and phase 1\/2 extension study in patients without inhibitors","volume":"128","author":"Ragni","year":"2016","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia a or b with investigational siRNA therapeutic fitusiran-results of the phase 1 inhibitor cohort","volume":"19","author":"Pasi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S159297","article-title":"An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia a and b","volume":"9","author":"Machin","year":"2018","journal-title":"J Blood Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/hae.14551","article-title":"Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022","author":"Mancuso","year":"2022","journal-title":"Haemophilia"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000281","article-title":"Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia","volume":"134","author":"Aymonnier","year":"2019","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15554","article-title":"(TaSER): A dual-action antithrombotic agent that targets platelets for SERPIN delivery","volume":"20","author":"Sanrattana","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2108458118","article-title":"A reactive center loop-based prediction platform to enhance the design of therapeutic SERPINs","volume":"118","author":"Sanrattana","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718635","article-title":"Design and characterization of an APC-specific serpin for the treatment of hemophilia","volume":"129","author":"Polderdijk","year":"2017","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1716751","article-title":"Serpins, new therapeutic targets for hemophilia","volume":"121","author":"Aymonnier","year":"2021","journal-title":"Thromb Haemost"},{"key":"B133","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1038\/s41467-020-16720-9","article-title":"Targeted inhibition of activated protein c by a non-active-site inhibitory antibody to treat hemophilia","volume":"11","author":"Zhao","year":"2020","journal-title":"Nat Commun"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013119","article-title":"Selective inhibition of activated protein c anticoagulant activity protects against hemophilic arthropathy in mice","volume":"139","author":"Magisetty","year":"2022","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015776","article-title":"Blocking hemophilic arthropathy","volume":"139","author":"Shi","year":"2022","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-016-1699-x","article-title":"Genome-editing technologies for gene correction of hemophilia","volume":"135","author":"Park","year":"2016","journal-title":"Hum Genet"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia a","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"key":"B138","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMc2204934","article-title":"Gene therapy for hemophilia a. reply","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"key":"B139","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia a","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17580","article-title":"Haemophilia: factoring in new therapies","volume":"194","author":"Fassel","year":"2021","journal-title":"Br J Haematol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A molecular revolution in the treatment of hemophilia","volume":"28","author":"Butterfield","year":"2020","journal-title":"Mol Ther"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia b: a single-centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","author":"Samelson-Jones","year":"2022","journal-title":"Annu Rev Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00618","article-title":"Translational potential of immune tolerance induction by AAV liver-directed factor VIII gene therapy for hemophilia a","volume":"11","author":"Samelson-Jones","year":"2020","journal-title":"Front Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to factor VIII in canine hemophilia a after liver gene therapy","volume":"116","author":"Finn","year":"2010","journal-title":"Blood"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13331","article-title":"Gene therapy for immune tolerance induction in hemophilia with inhibitors","volume":"14","author":"Arruda","year":"2016","journal-title":"J Thromb Haemost"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037671","article-title":"Transient b cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy","volume":"7","author":"Sack","year":"2012","journal-title":"PLoS One"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00502","article-title":"Anti-CD20 as the b-cell targeting agent in a combined therapy to modulate anti-factor VIII immune responses in hemophilia a inhibitor mice","volume":"4","author":"Liu","year":"2014","journal-title":"Front Immunol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cellimm.2016.01.005","article-title":"Strategies to target long-lived plasma cells for treating hemophilia a inhibitors","volume":"301","author":"Liu","year":"2016","journal-title":"Cell Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01293","article-title":"B cell depletion eliminates FVIII memory b cells and enhances AAV8-coF8 immune tolerance induction when combined with rapamycin","volume":"11","author":"Biswas","year":"2020","journal-title":"Front Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.111\/jth.14740","article-title":"Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia a patients with refractory","volume":"18","author":"Doshi","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.01.011","article-title":"Platelet-targeted gene therapy for hemophilia","volume":"9","author":"Shi","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29861","article-title":"In vivo enrichment of genetically manipulated platelets for murine hemophilia b gene therapy","volume":"236","author":"Chen","year":"2021","journal-title":"J Cell Physiol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.197","article-title":"Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice","volume":"22","author":"Chen","year":"2014","journal-title":"Mol Ther"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04791.x","article-title":"Lentivirus-mediated platelet gene therapy of murine hemophilia a with pre-existing anti-factor VIII immunity","volume":"10","author":"Kuether","year":"2012","journal-title":"J Thromb Haemost"},{"key":"B156","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12959-016-0105-1","article-title":"Hemophilia a gene therapy via intraosseous delivery of factor VIII-lentiviral vectors","volume":"14","author":"Miao","year":"2016","journal-title":"Thromb J"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-138214","article-title":"Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia a mice with preexisting FVIII immunity","volume":"112","author":"Shi","year":"2008","journal-title":"Blood"},{"key":"B158","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1038\/ncomms3773","article-title":"Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia a","volume":"4","author":"Du","year":"2013","journal-title":"Nat Commun"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-528737","article-title":"Suppression of inhibitor formation against FVIII in a murine model of hemophilia a by oral delivery of antigens bioencapsulated in plant cells","volume":"124","author":"Sherman","year":"2014","journal-title":"Blood"},{"key":"B160","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40779-022-00373-4","article-title":"Alterations of gut microbiota diversity, composition and metabonomics in testosterone-induced benign prostatic hyperplasia rats","volume":"9","author":"Li","year":"2022","journal-title":"Mil Med Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00844","article-title":"Role of small intestine and gut microbiome in plant-based oral tolerance for hemophilia","volume":"11","author":"Kumar","year":"2020","journal-title":"Front Immunol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.02.025","article-title":"Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD","volume":"30","author":"Landwehr-Kenzel","year":"2022","journal-title":"Mol Ther"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and b-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02359","article-title":"Chimeric antigen receptor (CAR) treg: A promising approach to inducing immunological tolerance","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Immunol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01998-7","article-title":"CAR treg cells: prime suspects in therapeutic resistance","volume":"28","author":"Saini","year":"2022","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1019275\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T15:18:29Z","timestamp":1670512709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1019275\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":166,"alternative-id":["10.3389\/fimmu.2022.1019275"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1019275","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"article-number":"1019275"}}